الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 106 |  |  |
| | | from | 106 | | |
Abstract
This study was conducted to compare the safety and efficacy of
rivaroxaban as compared to warfarin in treating acute lower limb DVT. A
130 patients were treated with both drugs 65 patients each and were observed
for the resulting outcomes of thrombus resolution and development of
complications over 6 months of follow up starting from March 2021 to April
2022. They were diagnosed with acute lower limb DVT using Wells score
and doppler ultrasonography to confirm the diagnosis. For the entire study
patients were followed up for the development of complications and for
thrombus resolution. To do so we notified the patients to return for a follow
up visit at 3 and 6 months of the start of their treatment and we repeated the
doppler ultrasonography at each visit and the size of the thrombus was
observed and compared with the initial thrombus size at the time of
diagnosis. Moreover, we recorded any events of bleeding reported by the
studied individuals and D-dimer, V/Q perfusion scintigraphy, MDCT
angiography and/or pulmonary angiography were ordered for those who
were suspected to develop pulmonary embolism. We found that there is no
statistical significance between rivaroxaban and warfarin as regarding their
efficacy and safety in treating acute lower limb DVT. However, we can
safely say that rivaroxaban has an upper hand to warfarin as it does not
require a bridge therapy with enoxaparin or require laboratory monitoring
and dose adjustment.